News

Spectramax Light Therapy Shows Promise in Easing Parkinson’s Non-motor Symptoms

PhotoPharmics’s Spectramax light therapy reduces disease severity, lessens non-motor symptoms, and improves the quality of life of Parkinson’s patients, according to recent results of a controlled clinical study. The study,“Double-blind controlled trial of Spectramaxâ„¢ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic…

Biogen Presents Data on Potential Therapies for Parkinson’s and Progressive Supranuclear Palsy

Biogen has presented data of its research programs evaluating potential treatments for Parkinson’s disease and progressive supranuclear palsy, an atypical parkinsonian disorder (APD). The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), held Oct. 5-9, in Hong Kong, China. Parkinson’s disease…

Parkinson’s Institute and Clinical Center, Retrotope Collaboration to Test RT001 in Progressive Supranuclear Palsy

Parkinson’s Institute and Clinical Center and Retrotope have paired up to explore the therapeutic potential of the investigational agent RT001 in patients with progressive supranuclear palsy (PSP), a type of treatment-resistant Parkinson’s disease. Under Retrotope’s expanded access program for RT001, the institute’s physicians started dosing two…